Rings in Clinical Trials and Drugs: Present and Future.
Shearer J, Castro JL, Lawson ADG, MacCoss M, Taylor RD. · 2022
Read Rings in Clinical Trials and Drugs: Present and Future. by Shearer J, Castro JL, Lawson ADG, MacCoss M, Taylor RD. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9289879.txt.
Description
Shearer and co-authors analyze ring systems, the cyclic cores found in drug molecules, across trials and approved drugs. They catalog every ring type in clinical trial compounds and in medicines cleared by the FDA. Ring choice shapes whether a molecule can become a drug. The pool in known chemical space is vast.
They count about 450,000 unique ring systems among 2.24 billion available molecules. Trial compounds use only 0.1% of that pool. Also, 67% of trial small molecules use only rings already found in marketed drugs. Drugs reuse their rings more often than trial compounds do. Small edits to known rings yield 3,902 candidate future rings. Those are predicted to cover about half of new rings entering trials.
Catalog record
| CREATOR | Shearer J, Castro JL, Lawson ADG, MacCoss M, Taylor RD. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |